Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B

[1]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[2]  B. Rehermann.  Natural Killer Cells in Viral Hepatitis , 2015, Cellular and molecular gastroenterology and hepatology.

[3]  G. Pedrazzi,et al.  Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B , 2015, Hepatology.

[4]  A. Bertoletti,et al.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections , 2015, Hepatology.

[5]  Xuan Huang,et al.  Circulating chemokine (C‐X‐C Motif) receptor 5+CD4+ T cells benefit hepatitis B e antigen seroconversion through IL‐21 in patients with chronic hepatitis B virus infection , 2013, Hepatology.

[6]  Qin Ning,et al.  KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure. , 2013, Clinical immunology.

[7]  C. Brander,et al.  Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. , 2013, Journal of hepatology.

[8]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[9]  A. Bertoletti,et al.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection , 2011, Gut.

[10]  Lanjuan Li,et al.  Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. , 2011, Antiviral research.

[11]  S. Sarin,et al.  Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate , 2011, Journal of Clinical Immunology.

[12]  H. Janssen,et al.  Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. , 2011, Journal of hepatology.

[13]  M. Maini,et al.  Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection , 2010, PLoS pathogens.

[14]  Antonio Bertoletti,et al.  The Host–pathogen Interaction during HBV Infection: Immunological Controversies , 2010, Antiviral therapy.

[15]  Q. Ning,et al.  Telbivudine preserves T‐helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis , 2010, Journal of viral hepatitis.

[16]  Q. Ning,et al.  Increased Killing of Liver NK Cells by Fas/Fas Ligand and NKG2D/NKG2D Ligand Contributes to Hepatocyte Necrosis in Virus-Induced Liver Failure , 2009, The Journal of Immunology.

[17]  S. Chokshi,et al.  Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e‐antigen seroconversion , 2008, Hepatology.

[18]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[19]  Z. Tian,et al.  Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. , 2008, Cytokine.

[20]  Govind Bhagat,et al.  Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. , 2004, Immunity.

[21]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[22]  A. Holý,et al.  Activation by 9-(R)-[2-(Phosphonomethoxy)Propyl]Adenine of Chemokine (RANTES, Macrophage Inflammatory Protein 1α) and Cytokine (Tumor Necrosis Factor Alpha, Interleukin-10 [IL-10], IL-1β) Production , 2001, Antimicrobial Agents and Chemotherapy.